Gilead Sciences, Inc.
GILDHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframePart of the healthcare sector, Gilead Sciences, Inc. (GILD) is listed under Drug Manufacturers - General. Valued at $193.48B, GILD is a large-cap name in its sector. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Market Cap
$193.48B
Beta
0.33
P/E (TTM)
—
P/E (Fwd)
15.64
EPS (TTM)
$-2.65
EPS (Fwd)
$9.97
ROE
-20.7%
ROA
14.1%
Cash
$4.88B
Total Debt
$26.25B
Free CF
$9.77B
52W Change
29.5%
Annual Financials
Cash vs Debt
Where GILD stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, GILD finished 14.51% above its 150-day moving average ($136.40) and 14.29% above its 200-day moving average ($136.66). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GILD overbought or oversold?
At the October 19, 2026 close, GILD's RSI(14) was 56.9, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, GILD has $4.88B in cash with $26.25B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $9.77B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -20.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 14.1% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $27.28B (2022) to $29.44B (2025).
GILD's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing GILD.